Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 6, 2014 (12 years ago)

Ketorolac Tromethamine Inj.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Ketorolac Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Single-dose Fliptop Vial, packaged in 25 Units per carton, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-3796-01.

Affected NDC 0409-3796-01

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ketorolac Tromethamine
NDC 00409-3796
60 mg/2mL Injection, Solution
Intramuscular
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
0409-3796-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0388-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by Hospira Inc.

All 2014 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016